샘플 요청 목록

 카트 문의
시장보고서
상품코드
1793875

세계의 전신성 소아특발성관절염 시장

Systemic Juvenile Idiopathic Arthritis
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 365 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 전신성 소아특발성관절염 시장은 2030년까지 22억 달러에 도달

2024년에 18억 달러로 추정되는 세계의 전신성 소아특발성관절염 시장은 2024-2030년의 분석 기간에 CAGR 3.7%로 성장하며, 2030년에는 22억 달러에 달할 것으로 예측됩니다. 이 리포트에서 분석한 부문의 하나인 약제 치료는 CAGR 4.4%를 기록하며, 분석 기간 종료시에는 15억 달러에 달할 것으로 예상됩니다. 생물제제 치료 부문의 성장률은 분석 기간 중 CAGR 2.1%로 추정됩니다.

미국 시장은 4억 8,370만 달러로 추정, 중국은 CAGR 6.9%로 성장 예측

미국의 전신성 소아특발성관절염 시장은 2024년에 4억 8,370만 달러로 추정됩니다. 세계 2위의 경제대국인 중국은 분석 기간인 2024-2030년 CAGR을 6.9%로, 2030년까지 4억 4,570만 달러의 시장 규모에 달할 것으로 예측됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 1.4%와 2.9%로 예측됩니다. 유럽에서는 독일이 CAGR 2.1%로 성장할 것으로 예측됩니다.

세계의 전신성 소아특발성관절염 시장 - 주요 동향과 촉진요인 정리

전신형 청소년 특발성 관절염이 소아 자가면역 치료에서 임상적으로 우선순위가 높은 이유는 무엇인가?

전신형 청소년 특발성 관절염(sJIA)은 전신 염증, 지속적인 발열, 발진, 관절 부종을 특징으로 하는 드물지만 심각한 청소년 특발성 관절염의 아형입니다. 다른 관절염과 달리 sJIA는 IL-1, IL-6와 같은 사이토카인의 조절 이상이 관여하는 자가 염증성 질환으로 여겨지고 있습니다. sJIA는 대식세포 활성화 증후군(MAS)과 같은 합병증의 가능성을 포함하여 전신에 영향을 미치기 때문에 조기 진단과 적극적인 개입이 필요합니다. 이 질환은 경과를 예측할 수 없고, 감염 및 혈액 질환과 증상이 중복되어 정확한 진단이 어려워 첨단 바이오마커 및 표적 생물제제에 대한 의존도가 높아지고 있습니다. 소아과 의사와 류마티스 전문의들 사이에서 인식이 높아짐에 따라 장기적인 결과와 삶의 질을 개선하기 위한 조기 진단 프로토콜과 맞춤 치료 전략 개발에 대한 관심이 높아지고 있습니다.

치료 혁신은 sJIA의 치료 경로를 어떻게 변화시킬 것인가?

주요 염증 매개체를 표적으로 삼는 생물제제는 치료의 전망에 혁명을 일으키고 있습니다. 아나킨라(IL-1 차단제)와 토실리주맙(IL-6 차단제)과 같은 인터류킨 억제제는 현재 중등도에서 중증의 sJIA의 표준 치료제로서 신속한 증상 조절과 코르티코스테로이드 의존성 감소를 제공합니다. JAK 억제제를 포함한 새로운 치료법은 난치성 환자 관리 및 재발 방지를 위해 임상시험에서 검토되고 있습니다. 바이오마커 중심의 접근법은 보다 정확한 치료 표적과 모니터링을 가능하게 하고 있습니다. 유전자 스크리닝, 사이토카인 프로파일링, 질병 활성도 점수 시스템은 치료 요법을 조정하는 데 도움이 되고 있습니다. 또한 피하주사 제제 및 장기지속형 주사제제의 발전으로 소아 환자의 순응도가 향상되고 있습니다. 이러한 기술 혁신은 질병의 완화와 장기적인 관절 및 장기 장애 예방에 기여하고 있습니다.

sJIA의 관리는 헬스케어의 통합을 통해 어디에서 개선되고 있는가?

sJIA의 관리는 소아 류마티스 전문의, 면역 전문의, 유전 전문의를 포함한 연계 진료 경로를 통해 개선되고 있습니다. 북미, 유럽, 아시아 일부 지역에 sJIA 전문 클리닉과 의뢰 센터가 설립되어 종합적인 치료와 임상시험 치료를 받을 수 있는 기회를 제공합니다. 원격의료 플랫폼은 특히 원격지나 의료 서비스가 부족한 지역에서 질병 모니터링과 복약 순응도를 향상시키고 있습니다. 환자 등록 및 리얼월드에비던스(RWE) 연구는 장기적으로 약물의 효과와 안전성을 추적하고 치료 지침과 규제 결정에 정보를 제공하기 위해 활용되고 있습니다. 정부 의료 기관과 소아과 옹호 단체들도 조기 개입 프로그램 및 인식 개선 캠페인에 자금을 지원하여 진단 지연을 줄이는 데 도움을 주고 있습니다. 이러한 협력적 노력으로 전 세계에서 sJIA 환자들의 접근성과 치료의 질이 향상되고 있습니다.

전신형 청소년 특발성 관절염 시장의 성장은 몇 가지 요인에 의해 주도되고 있습니다.

소아 자가면역질환의 발병률 증가, 사이토카인 표적 생물제제의 발전, 진단 프로토콜의 개선 등이 그 원동력입니다. IL-1 억제제와 IL-6 억제제의 승인은 효과적이고 스테로이드를 절약할 수 있는 치료 요법의 새로운 기준을 확립했습니다. 또한 차세대 생물제제나 JAK 억제제 등 경구용 저분자를 연구하는 소아 임상시험도 성장을 지원하고 있습니다. 소아 류마티스 진료의 확대와 sJIA의 희귀질환 등록으로 환자 발굴 및 치료 접근성이 향상되고 있습니다. 헬스케어 정책 강화, 디지털 모니터링 툴, 간병인 교육 플랫폼은 장기적인 질병 관리를 더욱 지원하고 있습니다.

부문

치료 유형(약물 치료, 생물제제 치료, 기타 치료 유형), 투여 루트(경구 루트, 주사 루트, 기타 투여 루트), 유통 채널(병원 약국, 소매 약국, 온라인 유통 채널)

조사 대상 기업의 예

  • AbbVie
  • Alteogen Inc.
  • AstraZeneca
  • Bristol-Myers Squibb(BMS)
  • Cadila Healthcare Ltd.
  • Celltrion Healthcare
  • Eli Lilly and Company
  • Epirus Biopharmaceuticals, Inc.
  • Genentech(Roche)
  • Hoffmann-La Roche Ltd.
  • Incyte Corporation
  • Johnson & Johnson(Janssen)
  • LATAM Pharma
  • Momenta Pharmaceuticals, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • Takeda Pharmaceutical Company Ltd.
  • UCB SA
  • Zydus Cadila**(Cadila Healthcare)

AI 통합

당사는 유효한 전문가 컨텐츠와 AI 툴에 의해 시장 정보와 경쟁 정보를 변혁하고 있습니다.

Global Industry Analysts는 LLM나 업계 고유 SLM를 조회하는 일반적인 규범에 따르는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수입원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

목차

제1장 조사 방법

제2장 개요

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSA 25.08.28

Global Systemic Juvenile Idiopathic Arthritis Market to Reach US$2.2 Billion by 2030

The global market for Systemic Juvenile Idiopathic Arthritis estimated at US$1.8 Billion in the year 2024, is expected to reach US$2.2 Billion by 2030, growing at a CAGR of 3.7% over the analysis period 2024-2030. Drug Treatment, one of the segments analyzed in the report, is expected to record a 4.4% CAGR and reach US$1.5 Billion by the end of the analysis period. Growth in the Biologics Treatment segment is estimated at 2.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$483.7 Million While China is Forecast to Grow at 6.9% CAGR

The Systemic Juvenile Idiopathic Arthritis market in the U.S. is estimated at US$483.7 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$445.7 Million by the year 2030 trailing a CAGR of 6.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.4% and 2.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.1% CAGR.

Global Systemic Juvenile Idiopathic Arthritis Market - Key Trends & Drivers Summarized

Why Is Systemic Juvenile Idiopathic Arthritis a Clinical Priority in Pediatric Autoimmune Care?

Systemic Juvenile Idiopathic Arthritis (sJIA) is a rare but severe subtype of juvenile idiopathic arthritis characterized by systemic inflammation, persistent fever, rash, and joint swelling. Unlike other forms of arthritis, sJIA is considered an autoinflammatory disease, often involving the dysregulation of cytokines such as IL-1 and IL-6. Due to its systemic impact-including potential complications like macrophage activation syndrome (MAS)-sJIA demands early diagnosis and aggressive intervention. The condition’s unpredictable course and overlapping symptoms with infectious or hematologic diseases make accurate diagnosis challenging, increasing the reliance on advanced biomarkers and targeted biologics. As awareness grows among pediatricians and rheumatologists, there is heightened focus on developing early diagnostic protocols and personalized treatment strategies to improve long-term outcomes and quality of life.

How Are Therapeutic Innovations Transforming sJIA Treatment Pathways?

Biologic therapies targeting key inflammatory mediators are revolutionizing the treatment landscape. Interleukin inhibitors such as anakinra (IL-1 blocker) and tocilizumab (IL-6 blocker) are now standard-of-care for moderate to severe sJIA, offering rapid symptom control and reduced corticosteroid dependence. Newer therapies including JAK inhibitors are being explored in clinical trials to manage refractory cases and prevent relapse. Biomarker-driven approaches are enabling more precise therapeutic targeting and monitoring. Genetic screening, cytokine profiling, and disease activity scoring systems are helping tailor treatment regimens. Additionally, advancements in subcutaneous and long-acting injectable formulations are improving adherence in pediatric patients. These innovations are contributing to disease remission and prevention of long-term joint and organ damage.

Where Is sJIA Management Improving Through Systemic Healthcare Integration?

sJIA management is being improved through coordinated care pathways involving pediatric rheumatologists, immunologists, and geneticists. Specialized sJIA clinics and referral centers are being established in North America, Europe, and parts of Asia to provide multidisciplinary care and access to investigational treatments. Telehealth platforms are enhancing disease monitoring and medication adherence, especially in remote or underserved regions. Patient registries and real-world evidence (RWE) studies are being used to track long-term drug effectiveness and safety, informing treatment guidelines and regulatory decisions. Government health agencies and pediatric advocacy groups are also funding early intervention programs and public awareness campaigns, helping reduce diagnostic delays. These collaborative efforts are enhancing both access to and the quality of care for sJIA patients globally.

The Growth in the Systemic Juvenile Idiopathic Arthritis Market Is Driven by Several Factors…

It is driven by increasing incidence of pediatric autoimmune diseases, advancements in cytokine-targeted biologics, and improved diagnostic protocols. The approval of IL-1 and IL-6 inhibitors has established new standards in effective, steroid-sparing treatment regimens. Growth is also supported by pediatric clinical trials investigating next-generation biologics and oral small molecules such as JAK inhibitors. Expansion of pediatric rheumatology services and inclusion of sJIA in rare disease registries are increasing patient identification and therapeutic access. Enhanced healthcare policies, digital monitoring tools, and caregiver education platforms are further supporting long-term disease management.

SCOPE OF STUDY:

The report analyzes the Systemic Juvenile Idiopathic Arthritis market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Treatment Type (Drug Treatment, Biologics Treatment, Other Treatment Types); Administration Route (Oral Route, Injectable Route, Other Routes of Administration); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Distribution Channel)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 32 Featured) -

  • AbbVie
  • Alteogen Inc.
  • AstraZeneca
  • Bristol-Myers Squibb (BMS)
  • Cadila Healthcare Ltd.
  • Celltrion Healthcare
  • Eli Lilly and Company
  • Epirus Biopharmaceuticals, Inc.
  • Genentech (Roche)
  • Hoffmann-La Roche Ltd.
  • Incyte Corporation
  • Johnson & Johnson (Janssen)
  • LATAM Pharma
  • Momenta Pharmaceuticals, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • Takeda Pharmaceutical Company Ltd.
  • UCB SA
  • Zydus Cadila** (Cadila Healthcare)

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Systemic Juvenile Idiopathic Arthritis - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Awareness and Early Diagnosis Rates of Pediatric Autoimmune Conditions Drive sJIA Treatment Demand
    • Rising Use of Biologics and Targeted Therapies Expands Treatment Options for Severe Cases
    • Advancements in Interleukin Inhibitor Research Propel Innovation in sJIA Drug Development
    • Improved Understanding of Disease Pathophysiology Enhances Precision in Treatment Selection
    • Expansion of Pediatric Rheumatology Clinics Increases Access to Specialized Care
    • Inclusion of sJIA Treatments in National Formularies Supports Prescription Growth
    • Rising Availability of Subcutaneous and At-Home Therapy Options Improves Patient Adherence
    • Ongoing Clinical Trials for Corticosteroid-Sparing Therapies Fuel Pipeline Interest
    • Growth in Companion Diagnostic Use Strengthens Market for Personalized Medicine in sJIA
    • Education and Advocacy Among Caregivers and Physicians Drive Early Intervention Trends
    • Monitoring of Long-Term Side Effects Spurs Interest in Safer, More Targeted Treatment Regimens
    • Use of Multidisciplinary Care Models Increases Treatment Consistency and Outcomes in Pediatric Patients
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Systemic Juvenile Idiopathic Arthritis Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Systemic Juvenile Idiopathic Arthritis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Drug Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Drug Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Drug Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Biologics Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Biologics Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Biologics Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Other Treatment Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Other Treatment Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Other Treatment Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Oral Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Oral Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Oral Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Injectable Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Injectable Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Injectable Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other Routes of Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other Routes of Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Other Routes of Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 31: World 16-Year Perspective for Online Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Systemic Juvenile Idiopathic Arthritis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 34: USA 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Percentage Breakdown of Value Sales for Drug Treatment, Biologics Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 37: USA 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Other Routes of Administration for the Years 2014, 2025 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 40: USA 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 43: Canada 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Percentage Breakdown of Value Sales for Drug Treatment, Biologics Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 46: Canada 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Other Routes of Administration for the Years 2014, 2025 & 2030
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 49: Canada 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • JAPAN
    • Systemic Juvenile Idiopathic Arthritis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 52: Japan 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Percentage Breakdown of Value Sales for Drug Treatment, Biologics Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 55: Japan 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Other Routes of Administration for the Years 2014, 2025 & 2030
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 58: Japan 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • CHINA
    • Systemic Juvenile Idiopathic Arthritis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 59: China Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 61: China 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Percentage Breakdown of Value Sales for Drug Treatment, Biologics Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 64: China 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Other Routes of Administration for the Years 2014, 2025 & 2030
    • TABLE 65: China Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 67: China 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • EUROPE
    • Systemic Juvenile Idiopathic Arthritis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Systemic Juvenile Idiopathic Arthritis by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 70: Europe 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 73: Europe 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Percentage Breakdown of Value Sales for Drug Treatment, Biologics Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 76: Europe 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Other Routes of Administration for the Years 2014, 2025 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 79: Europe 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • FRANCE
    • Systemic Juvenile Idiopathic Arthritis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 80: France Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: France Historic Review for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 82: France 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Percentage Breakdown of Value Sales for Drug Treatment, Biologics Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
    • TABLE 83: France Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 85: France 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Other Routes of Administration for the Years 2014, 2025 & 2030
    • TABLE 86: France Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 88: France 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • GERMANY
    • Systemic Juvenile Idiopathic Arthritis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 89: Germany Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Germany Historic Review for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 91: Germany 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Percentage Breakdown of Value Sales for Drug Treatment, Biologics Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 94: Germany 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Other Routes of Administration for the Years 2014, 2025 & 2030
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 97: Germany 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 100: Italy 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Percentage Breakdown of Value Sales for Drug Treatment, Biologics Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 103: Italy 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Other Routes of Administration for the Years 2014, 2025 & 2030
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 106: Italy 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Systemic Juvenile Idiopathic Arthritis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 107: UK Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 109: UK 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Percentage Breakdown of Value Sales for Drug Treatment, Biologics Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
    • TABLE 110: UK Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 112: UK 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Other Routes of Administration for the Years 2014, 2025 & 2030
    • TABLE 113: UK Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 115: UK 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 116: Spain Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Spain Historic Review for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 118: Spain 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Percentage Breakdown of Value Sales for Drug Treatment, Biologics Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
    • TABLE 119: Spain Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Spain Historic Review for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 121: Spain 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Other Routes of Administration for the Years 2014, 2025 & 2030
    • TABLE 122: Spain Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Spain Historic Review for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 124: Spain 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 125: Russia Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Russia Historic Review for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 127: Russia 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Percentage Breakdown of Value Sales for Drug Treatment, Biologics Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
    • TABLE 128: Russia Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Russia Historic Review for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 130: Russia 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Other Routes of Administration for the Years 2014, 2025 & 2030
    • TABLE 131: Russia Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Russia Historic Review for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 133: Russia 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Europe Historic Review for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 136: Rest of Europe 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Percentage Breakdown of Value Sales for Drug Treatment, Biologics Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
    • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of Europe Historic Review for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 139: Rest of Europe 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Other Routes of Administration for the Years 2014, 2025 & 2030
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 142: Rest of Europe 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Systemic Juvenile Idiopathic Arthritis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 144: Asia-Pacific Historic Review for Systemic Juvenile Idiopathic Arthritis by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 145: Asia-Pacific 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 148: Asia-Pacific 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Percentage Breakdown of Value Sales for Drug Treatment, Biologics Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 151: Asia-Pacific 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Other Routes of Administration for the Years 2014, 2025 & 2030
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 154: Asia-Pacific 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Systemic Juvenile Idiopathic Arthritis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 155: Australia Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Australia Historic Review for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 157: Australia 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Percentage Breakdown of Value Sales for Drug Treatment, Biologics Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
    • TABLE 158: Australia Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Australia Historic Review for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 160: Australia 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Other Routes of Administration for the Years 2014, 2025 & 2030
    • TABLE 161: Australia Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Australia Historic Review for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 163: Australia 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • INDIA
    • Systemic Juvenile Idiopathic Arthritis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 164: India Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: India Historic Review for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 166: India 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Percentage Breakdown of Value Sales for Drug Treatment, Biologics Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
    • TABLE 167: India Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: India Historic Review for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 169: India 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Other Routes of Administration for the Years 2014, 2025 & 2030
    • TABLE 170: India Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: India Historic Review for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 172: India 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 173: South Korea Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: South Korea Historic Review for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 175: South Korea 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Percentage Breakdown of Value Sales for Drug Treatment, Biologics Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
    • TABLE 176: South Korea Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: South Korea Historic Review for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 178: South Korea 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Other Routes of Administration for the Years 2014, 2025 & 2030
    • TABLE 179: South Korea Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: South Korea Historic Review for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 181: South Korea 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Rest of Asia-Pacific Historic Review for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 184: Rest of Asia-Pacific 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Percentage Breakdown of Value Sales for Drug Treatment, Biologics Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
    • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Rest of Asia-Pacific Historic Review for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 187: Rest of Asia-Pacific 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Other Routes of Administration for the Years 2014, 2025 & 2030
    • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Rest of Asia-Pacific Historic Review for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 190: Rest of Asia-Pacific 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Systemic Juvenile Idiopathic Arthritis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 191: Latin America Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 192: Latin America Historic Review for Systemic Juvenile Idiopathic Arthritis by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 193: Latin America 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 194: Latin America Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Latin America Historic Review for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 196: Latin America 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Percentage Breakdown of Value Sales for Drug Treatment, Biologics Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 199: Latin America 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Other Routes of Administration for the Years 2014, 2025 & 2030
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 202: Latin America 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 203: Argentina Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Argentina Historic Review for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 205: Argentina 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Percentage Breakdown of Value Sales for Drug Treatment, Biologics Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
    • TABLE 206: Argentina Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Argentina Historic Review for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 208: Argentina 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Other Routes of Administration for the Years 2014, 2025 & 2030
    • TABLE 209: Argentina Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Argentina Historic Review for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 211: Argentina 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 212: Brazil Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Brazil Historic Review for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 214: Brazil 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Percentage Breakdown of Value Sales for Drug Treatment, Biologics Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
    • TABLE 215: Brazil Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Brazil Historic Review for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 217: Brazil 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Other Routes of Administration for the Years 2014, 2025 & 2030
    • TABLE 218: Brazil Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Brazil Historic Review for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 220: Brazil 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 221: Mexico Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Mexico Historic Review for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 223: Mexico 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Percentage Breakdown of Value Sales for Drug Treatment, Biologics Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
    • TABLE 224: Mexico Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Mexico Historic Review for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 226: Mexico 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Other Routes of Administration for the Years 2014, 2025 & 2030
    • TABLE 227: Mexico Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Mexico Historic Review for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 229: Mexico 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Rest of Latin America Historic Review for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 232: Rest of Latin America 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Percentage Breakdown of Value Sales for Drug Treatment, Biologics Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
    • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Rest of Latin America Historic Review for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 235: Rest of Latin America 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Other Routes of Administration for the Years 2014, 2025 & 2030
    • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Rest of Latin America Historic Review for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 238: Rest of Latin America 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Systemic Juvenile Idiopathic Arthritis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 239: Middle East Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 240: Middle East Historic Review for Systemic Juvenile Idiopathic Arthritis by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 241: Middle East 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 242: Middle East Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Middle East Historic Review for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 244: Middle East 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Percentage Breakdown of Value Sales for Drug Treatment, Biologics Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 247: Middle East 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Other Routes of Administration for the Years 2014, 2025 & 2030
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 250: Middle East 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 251: Iran Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Iran Historic Review for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 253: Iran 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Percentage Breakdown of Value Sales for Drug Treatment, Biologics Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
    • TABLE 254: Iran Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Iran Historic Review for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 256: Iran 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Other Routes of Administration for the Years 2014, 2025 & 2030
    • TABLE 257: Iran Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Iran Historic Review for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 259: Iran 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 260: Israel Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Israel Historic Review for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 262: Israel 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Percentage Breakdown of Value Sales for Drug Treatment, Biologics Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
    • TABLE 263: Israel Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Israel Historic Review for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 265: Israel 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Other Routes of Administration for the Years 2014, 2025 & 2030
    • TABLE 266: Israel Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Israel Historic Review for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 268: Israel 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Saudi Arabia Historic Review for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 271: Saudi Arabia 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Percentage Breakdown of Value Sales for Drug Treatment, Biologics Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
    • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Saudi Arabia Historic Review for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 274: Saudi Arabia 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Other Routes of Administration for the Years 2014, 2025 & 2030
    • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Saudi Arabia Historic Review for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 277: Saudi Arabia 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 278: UAE Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 279: UAE Historic Review for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 280: UAE 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Percentage Breakdown of Value Sales for Drug Treatment, Biologics Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
    • TABLE 281: UAE Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 282: UAE Historic Review for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 283: UAE 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Other Routes of Administration for the Years 2014, 2025 & 2030
    • TABLE 284: UAE Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 285: UAE Historic Review for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 286: UAE 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Rest of Middle East Historic Review for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 289: Rest of Middle East 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Percentage Breakdown of Value Sales for Drug Treatment, Biologics Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
    • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Rest of Middle East Historic Review for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 292: Rest of Middle East 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Other Routes of Administration for the Years 2014, 2025 & 2030
    • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Rest of Middle East Historic Review for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 295: Rest of Middle East 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • AFRICA
    • Systemic Juvenile Idiopathic Arthritis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 296: Africa Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Africa Historic Review for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Drug Treatment, Biologics Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 298: Africa 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Treatment Type - Percentage Breakdown of Value Sales for Drug Treatment, Biologics Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
    • TABLE 299: Africa Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Africa Historic Review for Systemic Juvenile Idiopathic Arthritis by Administration Route - Oral Route, Injectable Route and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 301: Africa 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Other Routes of Administration for the Years 2014, 2025 & 2030
    • TABLE 302: Africa Recent Past, Current & Future Analysis for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Africa Historic Review for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 304: Africa 16-Year Perspective for Systemic Juvenile Idiopathic Arthritis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제